trending Market Intelligence /marketintelligence/en/news-insights/trending/FaxD_k2PABb5af0XoZYbfQ2 content esgSubNav
In This List

Takeda partners with private biotech company to develop liver disease therapies

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Takeda partners with private biotech company to develop liver disease therapies

Takeda Pharmaceutical Co. Ltd. signed an agreement with a privately held biotechnology company to discover and develop therapeutics for liver diseases.

While financial terms of the deal were not disclosed, HemoShear Therapeutics LLC will receive an upfront payment, research and development funding, up to $470 million in milestone-related payments, and royalties on the sales of any commercialized drug.

Takeda will receive exclusive access to HemoShear's proprietary disease modeling platform, REVEAL-Tx, to discover and develop therapeutics for specific liver diseases, including nonalcoholic steatohepatitis, or NASH, and liver fibrosis.

The U.S. Food and Drug Administration has yet to approve a treatment for NASH and liver fibrosis.

REVEAL-Tx replicates human diseases with great accuracy in clinical conditions to allow drug candidates to be studied at human concentrations.